Vulvar Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Vulvar Cancer Market is projected to increase from USD 650.78 Million in 2025 to USD 940.52 Million by 2031, registering a CAGR of 6.33%. This market comprises diagnostic technologies and therapeutic interventions, such as surgery, chemotherapy, and immunomodulators, designed to manage vulvar malignancies. Key factors driving this growth include an aging female population increasingly prone to vulvar neoplasia and a rising incidence of Human Papillomavirus infections, which are a primary cause of squamous cell carcinomas. Additionally, strong government programs focused on improving women's health are boosting early detection rates, thereby increasing the number of patients requiring timely medical treatment.

However, the market faces significant hurdles due to the high cost of advanced biologic therapies and the severe side effects often associated with radical surgical procedures. These financial and clinical barriers can discourage patient compliance and restrict market reach in developing nations with limited healthcare budgets. According to the American Cancer Society, approximately 7,480 new cases of vulvar cancer are expected to be diagnosed in the United States in 2025. This figure highlights the persistent burden of the disease, underscoring the need for manufacturers to focus on developing cost-effective and well-tolerated treatment innovations.

Market Drivers

The Global Vulvar Cancer Market is being significantly transformed by a strong pipeline of novel immunotherapies and targeted agents, providing new prospects for patients with advanced or recurrent conditions. Pharmaceutical developers are prioritizing immune checkpoint inhibitors to surpass the limitations of traditional chemoradiation, thereby improving efficacy for complex cases.

For example, Targeted Oncology reported in June 2025, in the article 'Pembrolizumab Combo Promising for Unresectable Vulvar Cancer', that a recent phase 2 clinical trial showed a 75% objective response rate in patients with locally advanced, unresectable squamous cell carcinoma when treated with a combination of pembrolizumab, cisplatin, and radiation. This rise in effective biologic agents is fueling market growth by widening the eligible patient base and promoting the adoption of premium therapeutic regimens.

Simultaneously, the increasing prevalence of Human Papillomavirus (HPV) infections acts as a major catalyst for market expansion, creating a need for improved preventative and therapeutic strategies. As infection rates endure, particularly among younger populations, the rise in HPV-linked malignancies continues to elevate the demand for specialized oncological care. The Centers for Disease Control and Prevention (CDC) noted in its December 2025 report 'Cancers Associated with Human Papillomavirus' that HPV is now estimated to cause approximately 69% of all vulvar cancers. This strong causal link emphasizes the urgent need for targeted interventions and strict screening programs; furthermore, the American Cancer Society estimates that 1,770 women in the United States will die from vulvar cancer in 2025, reinforcing the critical necessity for the continued development of advanced diagnostic and therapeutic solutions.

Market Challenges

The prohibitive costs associated with biologic therapies represent a major barrier to the expansion of the Global Vulvar Cancer Market. The high pricing structures of these agents create substantial economic obstacles, particularly in developing regions where healthcare budgets are constrained. When advanced treatments remain financially inaccessible, market penetration is severely curtailed, preventing manufacturers from optimizing revenue within these demographics. Consequently, the market struggles to achieve broad adoption, limiting its growth primarily to affluent segments rather than addressing the needs of the wider global patient population.

This economic restriction is compounded by clinical deterrents associated with radical surgical procedures, which frequently carry risks of severe side effects. Collectively, these factors create a gap between the prevalence of the disease and the utilization of available therapeutic interventions. This disparity is underscored by mortality data suggesting that current market mechanisms are not fully alleviating the disease burden. According to the American Cancer Society, approximately 1,770 deaths were projected to result from vulvar cancer in the United States in 2025. This statistic indicates that despite available technologies, economic and clinical hurdles continue to impede the successful delivery of care, directly hampering market growth.

Market Trends

The Global Vulvar Cancer Market is experiencing significant advancement in sentinel lymph node (SLN) mapping and biopsy protocols, shifting from traditional dye-based methods to fluorescence-guided techniques that reduce surgical morbidity. Clinicians are increasingly adopting indocyanine green (ICG) tracers to enhance the precision of nodal staging, thereby minimizing the incidence of lymphedema associated with complete lymphadenectomy. This transition is supported by compelling clinical data; according to Physician's Weekly in May 2025, in the article 'Indocyanine Green Matches Dual Tracers in Vulvar SLN Detection', a systematic review found that the per-patient sentinel lymph node detection rate for indocyanine green was 88%, proving it to be a highly effective and less invasive alternative to standard radiotracers.

Concurrently, the implementation of genomic profiling for personalized treatment plans is reshaping the therapeutic landscape, particularly for HPV-independent tumors which have historically lacked targeted options. Medical centers are incorporating next-generation sequencing into routine diagnostic workflows to identify actionable somatic mutations, facilitating the stratification of patients for emerging precision medicine therapies. This trend is substantiated by recent molecular characterization efforts; as reported by the International Journal of Gynecological Cancer in December 2024, in the article 'Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva', targeted sequencing revealed recurrent somatic mutations affecting TP53 in 68% of the studied cases, highlighting its potential as a critical biomarker for therapeutic selection.

Key Players Profiled in the Vulvar Cancer Market

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company

Report Scope

In this report, the Global Vulvar Cancer Market has been segmented into the following categories:

Vulvar Cancer Market, by Cancer Type:

• Vulvar Squamous Cell Carcinoma
• Vulvar Melanoma
• Adenocarcinoma
• Basal Cell Carcinoma

Vulvar Cancer Market, by Treatment Type:

• Chemotherapy
• Surgery
• Laser Surgery
• Excision
• Skinning Vulvectomy
• Radical Vulvectomy
• Radiation Vulvectomy
• Biologic Therapy

Vulvar Cancer Market, by End-User:

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Vulvar Cancer Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvar Cancer Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.